IGF1 and obesity disorder: In cases of suspected resistance, recombinant human IGF-1 (rhIGF-1) has been trialed as an alternative; however, one such report noted it did not provide substantial height benefits and was associated with side effects like obesity and acanthosis (Yang & Patni, 2020) (15).